Evidence map›Paper›PMID 30013329›Full record

ReviewPatient preference and adherence2018

Phosphate-control adherence in hemodialysis patients: current perspectives.

Ebele M Umeukeje, Amanda S Mixon, Kerri L Cavanaugh

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in Patient preference and adherence, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04789876 (A Multicenter, Open-Label, Randomised Controlled Trial Investigating the Effectiveness Of The Phosphate Mobile App on Serum Phosphorus Outcomes In Adult Hemodialysis Patients With Hyperphosphatemia), which is not on this map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04789876 nacompletednot on this mapstarted 2019, after this paper: background citation

A Multicenter, Open-Label, Randomised Controlled Trial Investigating the Effectiveness Of The Phosphate Mobile App on Serum Phosphorus Outcomes In Adult Hemodialysis Patients With Hyperphosphatemia

TypeinterventionalSponsorTaylor's UniversityRan2019 to 2020Enrolled74ConditionsHyperphosphatemia, End Stage Renal Disease on DialysisArmsPhosphate mobile app, One-off dietary counselling with a phosphate booklet
3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 53 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Medication adherence, health outcomes, and perceived social performance in Black Americans receiving hemodialysis.Health psychology : official journal of the Division of Health Psychology, American Psychological Association · 2026
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Ebele M UmeukejeVanderbilt Center for Kidney Disease, Nashville, TN, USA, ebele.m.umeukeje@vanderbilt.edu.
Amanda S MixonVanderbilt Center for Health Services Research, Nashville, TN, USA, ebele.m.umeukeje@vanderbilt.edu.
Kerri L CavanaughVanderbilt Center for Kidney Disease, Nashville, TN, USA, ebele.m.umeukeje@vanderbilt.edu.
Vanderbilt University · USVanderbilt Health · US

Funding

Building Interdisciplinary Research Careers in Women's HealthK12HD043483 · NICHD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HARTMANN, KATHERINE E, MAJOR, AMY S · 2002 to 2023
$10.3M
Determining Key Organizational Health Communication Practices in Complex PatientsR01DK103935 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI CAVANAUGH, KERRI · 2015 to 2019
$2.0M
NICHD NIH HHS K12 HD043483NIDDK NIH HHS R01 DK103935
6 · The paper itself

Abstract

objectivesThis review summarizes factors relevant for adherence to phosphate-control strategies in dialysis patients, and discusses interventions to overcome related challenges.

methodsA literature search including the terms "phosphorus", "phosphorus control", "hemo-dialysis", "phosphate binder medications", "phosphorus diet", "adherence", and "nonadherence" was undertaken using PubMed, PsycInfo, CINAHL, and Embase.

resultsHyperphosphatemia is associated with cardiovascular and all-cause mortality in dialysis patients. Management of hyperphosphatemia depends on phosphate binder medication therapy, a low-phosphorus diet, and dialysis. Phosphate binder therapy is associated with a survival benefit. Dietary restriction is complex because of the need to maintain adequate protein intake and, alone, is insufficient for phosphorus control. Similarly, conventional hemodialysis alone is insufficient for phosphorus control due to the kinetics of dialytic phosphorus removal. Thus, all three treatment approaches are important contributors, with dietary restriction and dialysis as adjuncts to the requisite phosphate binder therapy. Phosphate-control adherence rates are suboptimal and are influenced directly by patient, provider, and phosphorus-control strategy-related factors. Psychosocial factors have been implicated as influential "drivers" of adherence behaviors in dialysis patients, and factors based on self-motivation associate directly with adherence behavior. Higher-risk subgroups of nonadherent patients include younger dialysis patients and non-whites. Provider attitudes may be important - yet unaddressed - determinants of adherence behaviors of dialysis patients.

conclusionAdherence to phosphate binders, low-phosphorus diet, and dialysis prescription is suboptimal. Multicomponent strategies that concurrently address therapy-related factors such as side effects, patient factors targeting self-motivation, and provider factors to improve attitudes and delivery of culturally sensitive care show the most promise for long-term control of phosphorus levels. Moreover, it will be important to identify patients at highest risk for lack of control, and for programs to be ready to deliver flexible person-centered strategies through training and dedicated resources to align with the needs of all patients.

Indexed as

adherencedialysishyperphosphatemialow-phosphorus dietphosphorus binders

Identifiers

PMID30013329
PMCPMC6039061
OpenAlexW2810404796

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.